(Q45873478)

17 December 2017

title

Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). (English)

1 reference

17 December 2017

Cristian Rodriguez-Aguayo

C Ivan

12

0 references

13

object named as

C Rodriguez-Aguayo

1 reference

17 December 2017

6

H Hatakeyama

1 reference

17 December 2017

Gabriel Lopez-Berestein

15

object named as

G Lopez-Berestein

1 reference

17 December 2017

author name string

T Mitamura

1

1 reference

17 December 2017

S Pradeep

2

1 reference

17 December 2017

M McGuire

3

1 reference

17 December 2017

S Y Wu

4

1 reference

17 December 2017

S Ma

5

1 reference

17 December 2017

Y A Lyons

7

1 reference

17 December 2017

T Hisamatsu

8

1 reference

17 December 2017

K Noh

9

1 reference

17 December 2017

A Villar-Prados

10

1 reference

17 December 2017

X Chen

11

1 reference

17 December 2017

W Hu

14

1 reference

17 December 2017

R L Coleman

16

1 reference

17 December 2017

A K Sood

17

1 reference

17 December 2017

language of work or name

English

0 references

publication date

23 October 2017

1 reference

17 December 2017

published in

Oncogene

1 reference

17 December 2017

describes a project that uses

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6040890/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1038/onc.2017.348

0 references

cites work

CTCF: making the right connections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

The UCSC Genome Browser database: 2015 update

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

CTCF induces histone variant incorporation, erases the H3K27me3 histone mark and opens chromatin

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

PC3-secreted microprotein is a novel chemoattractant protein and functions as a high-affinity ligand for CC chemokine receptor 2.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

ENCODE data in the UCSC Genome Browser: year 5 update

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

A phase 3 trial of bevacizumab in ovarian cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Incorporation of bevacizumab in the primary treatment of ovarian cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Towards a knowledge-based Human Protein Atlas

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Tumour vascularization: sprouting angiogenesis and beyond

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Reactivity of a monoclonal antibody with human ovarian carcinoma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Comparative properties of five human ovarian adenocarcinoma cell lines.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6040890

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

29 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FONC.2017.348

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

31 March 2020

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FONC.2017.348

31 March 2020

Identifiers

DOI

10.1038/ONC.2017.348

1 reference

17 December 2017

Dimensions Publication ID

1092325782

0 references

PMC publication ID

6040890

0 references

1 reference

17 December 2017